Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, if his Department will implement the National Institute for Health and Care Excellence's latest guidance against the use of collagenase injections for the treatment of Dupuytren's disease.

The National Institute for Health and Care Excellence (NICE) has not yet published final guidance on the use of collagenase clostridium histolyticum (Xiapex) for treating Dupuytren’s contracture. We understand that NICE recently consulted with stakeholders on its draft recommendations and expects to issue its final guidance in April 2015.

In the absence of final guidance from NICE, it is for commissioners to make funding directions based on the available evidence.